Boston Scientific Corporation (BSX): The stock had negative money flow to the tune of ($5.5 million) on Friday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $23.99 million, whereas, the outflow of money on downticks was $29.49 million and the ratio between the two was 0.81. The block trade had a negative net money flow of ($5.25 million). The total block trade value undertaken on upticks was $5.03 million. On the other hand, downticks amounted to $10.28 million of the traded value, which shows distribution in the stock by traders. The ratio between uptick and downtick was 0.49. Boston Scientific Corporation (BSX) closed with marginal gains of 5 cents to end the day at $23.97, an increase of 0.2% over the previous days close. The stock recorded 1.65% for the week.
Boston Scientific Corporation (BSX) : Currently there are 19 street experts covering Boston Scientific Corporation (BSX) stock. The most bullish and bearish price target for the stock is $30 and $20 respectively for the short term. The average price target of all the analysts comes to $24.29. The estimated standard deviation from the target is $2.69.
Boston Scientific Corporation (NYSE:BSX): The stock was completely flat for the day, closing at $23.92 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $23.86, the stock touched an intraday high of $24.01 and a low of $23.70. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $23.92. The total trading volume on Friday was 11,054,201.
In a related news, The officer (SVP & Pres, Interven Cardio), of Boston Scientific Corp, Ballinger Kevin J. had unloaded 78,122 shares at $24.03 per share in a transaction on July 20, 2016. The total value of transaction was $1,877,272. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.